H-1B filings

Does Summit Therapeutics, Inc. sponsor H-1B?

Yes, according to public filings. Summit Therapeutics, Inc. filed 10 H-1B labor condition applications in fiscal years 2024-2026, including 2 in fiscal year 2026.

USCIS approved 10 H-1B petitions for this employer in fiscal years 2024-2026.

This page uses public government filings. A filing does not guarantee that the employer will sponsor you. This information is not legal advice.

Status on October 22, 2026: USCIS does not collect the $100,000 payment on new H-1B petitions for workers outside the U.S. while court orders stand. Appeals are pending, so this can change. USCIS H-1B FAQ

Labor condition applications by fiscal year

Fiscal yearFiledCertifiedWorkers
2026222
2025222
2024666

An employer files a labor condition application with the Department of Labor before it files an H-1B petition. A certified application is not an approved visa. The U.S. fiscal year runs from October 1 to September 30.

USCIS decisions on H-1B petitions by fiscal year

Fiscal yearNew: approvedNew: deniedContinuing: approvedContinuing: denied
20260020
20250020
20241050

New petitions are for first H-1B employment. Continuing petitions are for extensions and for workers who change employers.

Typical roles and wage ranges

Job titleApplicationsWage range per yearMedian
Senior Data Scientist2$168,500 - $173,000$173,000
Director, Business Development1$203,000 - $203,000$203,000
Director, Program Management1$235,000 - $235,000$235,000
Senior Clinical Trial Associate1$115,071 - $115,071$115,071
Senior Manager, Regulatory Affairs1$169,000 - $169,000$169,000
Senior Clinical Trial Manager1$177,000 - $177,000$177,000
Senior Manager/Associate Director - Oncology Market Planning1$208,024 - $208,024$208,024
Senior Accounting Manager1$169,000 - $169,000$169,000
IT Business Analyst1$130,572 - $130,572$130,572

Wages are the rates the employer stated in its applications. Actual pay can differ.

Top locations

LocationApplications
Menlo Park, CA9
Palo Alto, CA1

Sources

Data release 2026q3, built on October 23, 2026.